6 active not recruiting, 4 completed, 3 recruiting, 2 terminated. 12 Phase 2, 7 Phase 1, 2 Not applicable, 1 Early Phase 1.
Follow Stage IV Colon Cancer AJCC v8: new trials by email Literature Review of Stage IV Colon Cancer AJCC v8 trials Research Report on Stage IV Colon Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion Biospecimen Collection, Computed Tomography, Pemetrexed - Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma | Phase 1 / Phase 2 | Recruiting | Northwestern University | 72 | 2026-08-21 | 2026-08-25 |
| Family Communications After Genetic Testing Biospecimen Collection, Genetic Testing, Communication Intervention - Colon Adenocarcinoma, Colorectal Adenocarcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 4186 | 2026-04-06 | 2026-10-02 |
| Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer Balstilimab, Biopsy, Biospecimen Collection - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2024-11-01 | 2024-11-21 | |
| Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2023-10-31 | 2024-09-19 | |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Cetuximab, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-07-19 | 2026-07-08 |
| Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery NBT-NM108 - Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8 | Phase 2 | Recruiting | Howard S. Hochster, MD | 42 | 2022-05-03 | 2026-01-06 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events Best Practice, Patient Monitoring, Questionnaire Administration - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 750 | 2021-05-12 | 2026-06-16 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Early Phase 1 | Completed | University of Southern California | 10 | 2021-02-15 | 2024-05-24 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Ipilimumab, Nivolumab, Regorafenib - Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma | Phase 1 | Completed | City of Hope Medical Center | 39 | 2020-05-27 | 2026-01-28 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial Genetic Testing - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Terminated | Academic and Community Cancer Research United | 199 | 2020-04-20 | 2025-08-29 | |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2018-03-07 | 2024-11-27 |
Colonic Neoplasms (18) · Rectal Neoplasms (14) · Colorectal Neoplasms (12) · Neoplasm Metastasis (3) · Breast Neoplasms (2) · Esophageal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Glioma (1)
Colonic Diseases (18) · Digestive System Diseases (18) · Digestive System Neoplasms (18) · Gastrointestinal Diseases (18) · Intestinal Diseases (18) · Intestinal Neoplasms (18) · Neoplasms (18) · Neoplasms by Site (18) · Gastrointestinal Neoplasms (16) · Rectal Diseases (15) · Colorectal Neoplasms (6) · Head and Neck Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplastic Processes (3) · Pathologic Processes (3)
Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Nivolumab (3) · Trifluridine (3) · regorafenib (3) · trifluridine tipiracil drug combination (3) · Bevacizumab (2) · Biopsy (2) · Cetuximab (2) · Disulfides (2) · Genetic Testing (2) · balstilimab (2) · (225)Ac-DOTA-c(RGDyK) (1) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · CTLA-4 Antigen (1)
M.D. Anderson Cancer Center (4) · Academic and Community Cancer Research United (3) · City of Hope Medical Center (3) · National Cancer Institute (NCI) (3) · Alliance for Clinical Trials in Oncology (1) · Howard S. Hochster, MD (1) · Northwestern University (1) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (17) · Puerto Rico (2)
John H Strickler (4) · Marwan G Fakih (3) · Alisha Bent, MD (1) · Christine M Parseghian, MD (1) · Christos Fountzilas, MD (1) · Devalingam Mahalingam, MD, PhD (1) · Frank A Sinicrope (1) · Hossein Jadvar, MD (1) · Howard S Hochster, MD (1) · Kanwal P Raghav (1) · Ryan W Huey, MD (1) · Van K Morris (1) · Van K Morris, MD (1)
PMID 33109741, PMID 36821818, PMID 36892833, PMID 39244627, PMID 39652198
P30CA015083 (3), P30CA033572 (2), P30CA014089 (1), P30CA060553 (1), R01CA187238 (1), U10CA180888 (1), UM1CA186688 (1), UM1CA186704 (1)